Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome

Abstract

Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors' cases and published cases of eculizumab discontinuation are reviewed. We also report… (More)
DOI: 10.1093/ckj/sfw115

Topics

2 Figures and Tables

Slides referencing similar topics